bbc_business

Saudi Arabia to stop funding LIV Golf next season

saudi arabia is pulling its multi-billion dollar funding of liv golf after this season, throwing the breakaway tour's future into doubt. the series is "totally up for sale" and will announce a "new strategic plan" on thursday to find replacement investors.

the saudi public investment fund has poured over $5bn into liv since 2021, including a fresh $267m injection this year. the tour lost $462m in markets outside the us in 2024 alone, with total losses since launch exceeding $1.1bn. pif governor yasir al-rumayyan, who co-founded liv, is reportedly stepping down from the board.

liv postponed its june event in new orleans, leaving a gap in the us schedule from 10 may to 6 august. the tour remains hopeful of staying international with a team model, but officials accept it will likely have to scale back significantly from 14 events. liv says it's in "constructive" talks with potential investors and on course to earn $100m more in 2026 than last season.

source: bbc_business
sentiment: -0.30 · impact: 0.60

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds